MX2011004649A - Proteinas de union que inhiben la interaccion en el receptor de vegf-a. - Google Patents
Proteinas de union que inhiben la interaccion en el receptor de vegf-a.Info
- Publication number
- MX2011004649A MX2011004649A MX2011004649A MX2011004649A MX2011004649A MX 2011004649 A MX2011004649 A MX 2011004649A MX 2011004649 A MX2011004649 A MX 2011004649A MX 2011004649 A MX2011004649 A MX 2011004649A MX 2011004649 A MX2011004649 A MX 2011004649A
- Authority
- MX
- Mexico
- Prior art keywords
- repeated
- amino acid
- group
- residual amino
- vegf
- Prior art date
Links
- 108091008324 binding proteins Proteins 0.000 title claims abstract description 131
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 title abstract description 25
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title description 3
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 230000010799 Receptor Interactions Effects 0.000 title 1
- 230000027455 binding Effects 0.000 claims abstract description 130
- 102000023732 binding proteins Human genes 0.000 claims abstract description 130
- 108010049777 Ankyrins Proteins 0.000 claims abstract description 106
- 102000008102 Ankyrins Human genes 0.000 claims abstract description 106
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims abstract description 24
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims abstract description 23
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 208000030533 eye disease Diseases 0.000 claims abstract description 5
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims abstract 2
- 150000001413 amino acids Chemical class 0.000 claims description 197
- 229910052727 yttrium Inorganic materials 0.000 claims description 51
- 229910052739 hydrogen Inorganic materials 0.000 claims description 46
- 230000003993 interaction Effects 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 36
- 229910052757 nitrogen Inorganic materials 0.000 claims description 36
- 229910052731 fluorine Inorganic materials 0.000 claims description 31
- 229910052720 vanadium Inorganic materials 0.000 claims description 28
- 229910052740 iodine Inorganic materials 0.000 claims description 21
- 229910052700 potassium Inorganic materials 0.000 claims description 21
- 229910052717 sulfur Inorganic materials 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 80
- 102000004169 proteins and genes Human genes 0.000 abstract description 79
- 206010028980 Neoplasm Diseases 0.000 abstract description 30
- 206010064930 age-related macular degeneration Diseases 0.000 abstract description 12
- 201000011510 cancer Diseases 0.000 abstract description 12
- 208000002780 macular degeneration Diseases 0.000 abstract description 10
- 230000001575 pathological effect Effects 0.000 abstract description 6
- 235000001014 amino acid Nutrition 0.000 description 144
- 229940024606 amino acid Drugs 0.000 description 140
- 235000018102 proteins Nutrition 0.000 description 72
- 108090000765 processed proteins & peptides Proteins 0.000 description 57
- 229920001184 polypeptide Polymers 0.000 description 55
- 102000004196 processed proteins & peptides Human genes 0.000 description 55
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 39
- 210000001508 eye Anatomy 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 32
- 241000282414 Homo sapiens Species 0.000 description 24
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 23
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 238000002347 injection Methods 0.000 description 18
- 239000007924 injection Substances 0.000 description 18
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 16
- 239000002953 phosphate buffered saline Substances 0.000 description 16
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 15
- 102000001708 Protein Isoforms Human genes 0.000 description 14
- 108010029485 Protein Isoforms Proteins 0.000 description 14
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 14
- 229920001223 polyethylene glycol Polymers 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 13
- 239000002202 Polyethylene glycol Substances 0.000 description 13
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 11
- 229940120638 avastin Drugs 0.000 description 11
- 201000011190 diabetic macular edema Diseases 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 229940076783 lucentis Drugs 0.000 description 11
- 108020001580 protein domains Proteins 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 230000002792 vascular Effects 0.000 description 10
- 206010012689 Diabetic retinopathy Diseases 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 230000036425 denaturation Effects 0.000 description 9
- 238000004925 denaturation Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 102100035194 Placenta growth factor Human genes 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 206010038923 Retinopathy Diseases 0.000 description 7
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 7
- 230000033115 angiogenesis Effects 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 108091035707 Consensus sequence Proteins 0.000 description 6
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 6
- 230000001772 anti-angiogenic effect Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 229960002143 fluorescein Drugs 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 230000001394 metastastic effect Effects 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 230000001023 pro-angiogenic effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 208000017442 Retinal disease Diseases 0.000 description 4
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 239000000287 crude extract Substances 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229940050526 hydroxyethylstarch Drugs 0.000 description 4
- 108010087904 neutravidin Proteins 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 230000006320 pegylation Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 208000002815 pulmonary hypertension Diseases 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 3
- 206010055113 Breast cancer metastatic Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010029113 Neovascularisation Diseases 0.000 description 3
- 102000002111 Neuropilin Human genes 0.000 description 3
- 108050009450 Neuropilin Proteins 0.000 description 3
- 208000022873 Ocular disease Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 3
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 3
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000003606 umbilical vein Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 2
- 102000016904 Armadillo Domain Proteins Human genes 0.000 description 2
- 108010014223 Armadillo Domain Proteins Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 101100263580 Canis lupus familiaris VEGFA gene Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 206010024769 Local reaction Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 101000677856 Stenotrophomonas maltophilia (strain K279a) Actin-binding protein Smlt3054 Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 2
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000002983 circular dichroism Methods 0.000 description 2
- 238000000978 circular dichroism spectroscopy Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 102000058223 human VEGFA Human genes 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 208000023589 ischemic disease Diseases 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229940092110 macugen Drugs 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 229960003876 ranibizumab Drugs 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000013076 target substance Substances 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 238000002424 x-ray crystallography Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 1
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- 206010060934 Allergic oedema Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000000058 Anaplasia Diseases 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 102000009075 Angiopoietin-2 Human genes 0.000 description 1
- 102100034608 Angiopoietin-2 Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 201000005262 Chondroma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000289632 Dasypodidae Species 0.000 description 1
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 1
- 102000002090 Fibronectin type III Human genes 0.000 description 1
- 108050009401 Fibronectin type III Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000009774 Follicular Cyst Diseases 0.000 description 1
- 206010018001 Gastrointestinal perforation Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 208000008069 Geographic Atrophy Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000002125 Hemangioendothelioma Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010022773 Intracranial pressure increased Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 206010025538 Malignant ascites Diseases 0.000 description 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101001026869 Mus musculus F-box/LRR-repeat protein 3 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 208000008558 Osteophyte Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010034665 Peritoneal fibrosis Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241001662443 Phemeranthus parviflorus Species 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000255969 Pieris brassicae Species 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101900161471 Pseudomonas aeruginosa Exotoxin A Proteins 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- 206010037649 Pyogenic granuloma Diseases 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108050003978 Semaphorin Proteins 0.000 description 1
- 102000014105 Semaphorin Human genes 0.000 description 1
- 101000582398 Staphylococcus aureus Replication initiation protein Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- -1 VEGFR-2 binding) Chemical compound 0.000 description 1
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000034698 Vitreous haemorrhage Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 239000000561 aggregant Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 230000027746 artery morphogenesis Effects 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 101150030721 ata gene Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940020947 fluorescein sodium Drugs 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 201000009941 intracranial hypertension Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000012804 iterative process Methods 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 230000035168 lymphangiogenesis Effects 0.000 description 1
- 210000001077 lymphatic endothelium Anatomy 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960003407 pegaptanib Drugs 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 238000011197 physicochemical method Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
- 238000003157 protein complementation Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 210000001957 retinal vein Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 108010002164 tyrosine receptor Proteins 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08168166 | 2008-11-03 | ||
| PCT/EP2009/064483 WO2010060748A1 (en) | 2008-11-03 | 2009-11-03 | Binding proteins inhibiting the vegf-a receptor interaction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011004649A true MX2011004649A (es) | 2011-05-30 |
Family
ID=40149742
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011004649A MX2011004649A (es) | 2008-11-03 | 2009-11-03 | Proteinas de union que inhiben la interaccion en el receptor de vegf-a. |
| MX2015010520A MX359570B (es) | 2008-11-03 | 2009-11-03 | Proteinas de union que inhiben la interaccion en el receptor de vegf-a. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015010520A MX359570B (es) | 2008-11-03 | 2009-11-03 | Proteinas de union que inhiben la interaccion en el receptor de vegf-a. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8901076B2 (enExample) |
| EP (2) | EP2358746B1 (enExample) |
| JP (2) | JP5954990B2 (enExample) |
| KR (1) | KR101698362B1 (enExample) |
| CN (2) | CN102272148A (enExample) |
| AU (1) | AU2009319204B2 (enExample) |
| BR (1) | BRPI0921469B1 (enExample) |
| CA (1) | CA2742241C (enExample) |
| DK (1) | DK2358746T3 (enExample) |
| ES (1) | ES2836948T3 (enExample) |
| IL (1) | IL212589A (enExample) |
| MX (2) | MX2011004649A (enExample) |
| NZ (1) | NZ592591A (enExample) |
| RU (2) | RU2650765C1 (enExample) |
| WO (1) | WO2010060748A1 (enExample) |
Families Citing this family (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4976412B2 (ja) | 2005-12-01 | 2012-07-18 | ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー | エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法 |
| MY150400A (en) | 2006-04-07 | 2014-01-15 | Aerpio Therapeutics Inc | Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof |
| AU2014243418B2 (en) * | 2010-04-30 | 2016-09-22 | Molecular Partners Ag | Modified binding proteins inhibiting the VEGF-A receptor interaction |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| CA2818969C (en) * | 2010-11-26 | 2020-04-14 | Molecular Partners Ag | Improved n-terminal capping modules for designed ankyrin repeat proteins |
| AU2012249359A1 (en) | 2011-04-29 | 2013-11-14 | Janssen Biotech, Inc. | IL4/IL13 binding repeat proteins and uses |
| WO2012172054A1 (en) | 2011-06-16 | 2012-12-20 | Scil Proteins Gmbh | Modified multimeric ubiquitin proteins binding vegf-a |
| CN104039351A (zh) | 2011-10-13 | 2014-09-10 | 阿尔皮奥治疗学股份有限公司 | 用于治疗血管渗漏综合征和癌症的方法 |
| WO2013072510A1 (en) | 2011-11-16 | 2013-05-23 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
| ES2751492T3 (es) | 2011-11-16 | 2020-03-31 | Adrenomed Ag | Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o armazón no Ig anti-ADM para uso en la terapia de una enfermedad aguda o una afección aguda de un paciente para estabilizar la circulación |
| PT2780371T (pt) | 2011-11-16 | 2019-01-30 | Adrenomed Ag | Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou uma estrutura não ig anti-adm para a regulação do equilíbrio de fluidos num doente com uma doença aguda ou crónica |
| CN110054690B (zh) | 2011-11-16 | 2023-11-24 | 艾德里诺医药公司 | 用于治疗的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig骨架 |
| MY174877A (en) | 2011-11-16 | 2020-05-20 | Adrenomed Ag | Anti-adrenomedullin (adm) antibpdy or anti-adm antibody fragment of anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic of acute disease or acute condition |
| SG10202006318TA (en) | 2011-11-16 | 2020-08-28 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
| CN103308673B (zh) | 2012-03-08 | 2017-05-31 | 思芬构技术有限公司 | 用于预测雌性对象中发生心血管事件的风险的方法 |
| CN103308689B (zh) | 2012-03-08 | 2017-04-12 | 思芬构技术有限公司 | 用于预测雌性对象中患上癌症的风险或诊断癌症的方法 |
| CN103308670B (zh) | 2012-03-08 | 2017-06-09 | 思芬构技术有限公司 | 用于预测对象患糖尿病和/或代谢综合征的风险的方法 |
| DK2846836T3 (da) | 2012-05-07 | 2019-11-11 | Allergan Inc | Fremgangsmåde til behandling af amd hos patienter, der er refraktære overfor anti-vegf-terapi |
| LT3777834T (lt) | 2012-06-01 | 2022-05-25 | Novartis Ag | Švirkštas |
| BR112014032316A2 (pt) * | 2012-06-28 | 2017-06-27 | Molecular Partners Ag | proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta |
| AU2013100070B4 (en) * | 2012-07-03 | 2013-04-04 | Novartis Ag | Use of device |
| AU2012101677B4 (en) * | 2012-07-03 | 2012-12-20 | Novartis Ag | Device |
| JOP20200175A1 (ar) | 2012-07-03 | 2017-06-16 | Novartis Ag | حقنة |
| WO2014033184A1 (en) * | 2012-08-28 | 2014-03-06 | Novartis Ag | Use of a vegf antagonist in treating ocular vascular proliferative diseases |
| RU2707303C1 (ru) | 2012-10-02 | 2019-11-26 | Сфинготек Гмбх | Способ диагностики или мониторинга почечной функции или диагностики почечной дисфункции |
| EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| CA2897327A1 (en) | 2013-01-08 | 2014-07-17 | Sphingotec Gmbh | Fasting levels of growth hormone as a predictive marker of cardiovascular risk |
| CN105143270B (zh) * | 2013-02-26 | 2019-11-12 | 罗切格利卡特公司 | 双特异性t细胞活化抗原结合分子 |
| JP6649246B2 (ja) * | 2013-03-14 | 2020-02-19 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | タンパク質の徐放性送達の組成物及び製造プロセス中のタンパク質の安定化方法 |
| ES2830036T3 (es) | 2013-03-20 | 2021-06-02 | Sphingotec Gmbh | Adrenomedulina para guiar una terapia de disminución de la presión sanguínea |
| FR3004650B1 (fr) * | 2013-04-22 | 2015-05-29 | Affilogic | Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation |
| CN105209483B (zh) | 2013-05-31 | 2021-07-27 | 分子组合公司 | 与肝细胞生长因子结合的设计锚蛋白重复蛋白 |
| WO2014203182A1 (en) | 2013-06-20 | 2014-12-24 | Novartis Ag | Use of a vegf antagonist in treating choroidal neovascularisation |
| US20160129080A1 (en) | 2013-06-20 | 2016-05-12 | Aaron Osborne | Treatment of polypoidal chroidal vasculopathy |
| EP3010526A1 (en) | 2013-06-20 | 2016-04-27 | Novartis AG | Use of a vegf antagonist in treating macular edema |
| WO2015004616A1 (en) | 2013-07-11 | 2015-01-15 | Novartis Ag | Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients |
| JP2016523956A (ja) | 2013-07-11 | 2016-08-12 | ノバルティス アーゲー | 未熟児網膜症の治療におけるｖｅｇｆアンタゴニストの使用 |
| SG10201708882TA (en) | 2013-07-12 | 2017-12-28 | Ophthotech Corp | Methods for treating or preventing ophthalmological conditions |
| DK3065761T3 (da) * | 2013-11-05 | 2020-02-17 | Allergan Inc | Fremgangsmåde til behandling af tilstande af øjet med en anti-vegf darpin |
| US20170232199A1 (en) | 2014-05-12 | 2017-08-17 | Formycon Ag | Pre-Filled Plastic Syringe Containing a VEGF Antagonist |
| EP3002589A1 (en) | 2014-10-01 | 2016-04-06 | sphingotec GmbH | A method for stratifying a female subject for hormone replacement therapy |
| EP3277711B9 (en) | 2015-04-02 | 2023-08-16 | Molecular Partners AG | Designed ankyrin repeat domains with binding specificity for serum albumin |
| SG11201708655UA (en) | 2015-04-24 | 2017-11-29 | Sphingotec Gmbh | A method for predicting the risk of incidence of chronic kidney disease |
| TWI799366B (zh) | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | 胱胺酸結骨架平臺 |
| CA3005132A1 (en) | 2015-11-18 | 2017-05-26 | Sio2 Medical Products, Inc. | Coated syringe for ophthalmic formulations containing a vegf antagonist |
| KR20180083377A (ko) | 2015-11-18 | 2018-07-20 | 포르미콘 아게 | Vegf 안타고니스트를 함유하는 사전충전형 플라스틱 주사기 |
| CA3005117C (en) | 2015-11-18 | 2023-01-24 | Formycon Ag | Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist |
| AU2017213103B2 (en) | 2016-01-26 | 2022-08-11 | Formycon Ag | Liquid formulation of a VEGF antagonist |
| CN109073660B (zh) | 2016-02-29 | 2022-10-28 | 麦恩泰科特有限公司 | 可用于治疗湿性年龄相关性黄斑变性的预测性标志物 |
| KR102886883B1 (ko) | 2016-04-21 | 2025-11-19 | 4틴4 파마슈티컬스 게엠베하 | Dpp3을 결정하는 방법 및 치료 방법 |
| MA45493A (fr) | 2016-06-27 | 2019-05-01 | Aicuris Anti Infective Cures Gmbh | Inhibiteurs d'entrée de hcmv. |
| CN109716136B (zh) | 2016-07-08 | 2023-09-22 | 斯弗因高泰克有限公司 | 肾上腺髓质素用于评估急性心力衰竭患者的充血 |
| WO2018017714A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| AU2017331329B2 (en) | 2016-09-22 | 2020-10-29 | Molecular Partners Ag | Recombinant binding proteins and their use |
| EP3309550A1 (en) | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Method for the detection of apolipoprotein e4 |
| AU2017375049B2 (en) | 2016-12-16 | 2025-01-30 | Adrenomed Ag | Anti-Adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
| EP3339324A1 (en) | 2016-12-22 | 2018-06-27 | sphingotec GmbH | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
| EP3630062A2 (en) | 2017-05-24 | 2020-04-08 | SiO2 Medical Products, Inc. | Sterilizable pharmaceutical package for ophthalmic formulations |
| WO2018215580A1 (en) | 2017-05-24 | 2018-11-29 | Formycon Ag | Method for sterilizing prefilled plastic syringes containing a vegf antagonist |
| WO2018217995A1 (en) | 2017-05-24 | 2018-11-29 | Formycon Ag | Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist |
| MX2019014441A (es) | 2017-05-30 | 2020-02-10 | Sphingotec Gmbh | Un metodo in vitro para diagnosticar o monitorear la funcion renal o diagnosticar disfuncion renal. |
| TW201904610A (zh) | 2017-06-14 | 2019-02-01 | 德商拜耳製藥公司 | 用於治療新生血管型青光眼之非抗體vegf拮抗劑 |
| WO2019020777A1 (en) | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
| CA3073125A1 (en) | 2017-08-18 | 2019-02-21 | Cambridge Enterprise Limited | Modular binding proteins |
| CA3076691A1 (en) | 2017-09-25 | 2019-03-28 | Adrenomed Ag | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness |
| SG11202002268XA (en) | 2017-10-18 | 2020-04-29 | Adrenomed Ag | Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder |
| CN111542755A (zh) | 2017-10-24 | 2020-08-14 | 思芬构技术有限公司 | 用于预测第一次心血管事件的硒蛋白p |
| MX2020004271A (es) | 2017-10-25 | 2020-07-29 | 4TEEN4 Pharmaceuticals GmbH | Aglutinante de dpp3 dirigido a y que se une a epitopes de dpp3 especificos y su uso en la prevencion o tratamiento de enfermedades/condiciones agudas que estan asociadas con estres oxidativo. |
| MX421834B (es) | 2018-02-08 | 2025-03-14 | Sphingotec Gmbh | Adrenomedulina (adm) para el diagnostico y/o prediccion de demencia y un aglutinante de anti-adrenomedulina para usarse en la terapia o prevencion de demencia |
| EP3569614A1 (en) | 2018-05-18 | 2019-11-20 | Julius-Maximilians-Universität Würzburg | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase |
| EP3586865A1 (en) | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
| EP3856245A4 (en) | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF |
| MX2021007467A (es) | 2018-12-20 | 2021-08-05 | Sphingotec Gmbh | Selenoproteina p en insuficiencia cardiaca. |
| JP2022516438A (ja) | 2018-12-21 | 2022-02-28 | ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | アンジオテンシン受容体アゴニストおよび／またはその前駆体による治療のための治療ガイドおよび／または治療モニタリング |
| SG11202112921VA (en) | 2019-06-04 | 2021-12-30 | Molecular Partners Ag | Multispecific proteins |
| US20220291234A1 (en) | 2019-08-15 | 2022-09-15 | Sphingotec Gmbh | A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction in pediatric patients |
| EP4021571B1 (en) | 2019-08-30 | 2025-10-08 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for treatment of shock |
| CA3161321A1 (en) | 2019-12-11 | 2021-06-17 | Victor LEVITSKY | Recombinant peptide-mhc complex binding proteins and their generation and use |
| EP3871689A1 (en) | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| CN115244081A (zh) | 2020-02-27 | 2022-10-25 | 艾德里诺医药公司 | 用于治疗休克患者的抗肾上腺髓质素(adm)结合剂 |
| WO2021170876A1 (en) | 2020-02-27 | 2021-09-02 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| BR112022015215A2 (pt) | 2020-02-27 | 2022-10-11 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 para orientação, monitoramento e estratificação de terapia de anticorpos nt-adm em pacientes com choque |
| MX2022011581A (es) | 2020-03-16 | 2022-10-18 | Adrenomed Ag | Proadrenomedulina o fragmento de la misma en pacientes infectados con coronavirus y tratamientos con aglutinante contra la adrenomedulina. |
| US20230213519A1 (en) | 2020-03-16 | 2023-07-06 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| EP3922993A1 (en) | 2020-06-12 | 2021-12-15 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| WO2021224686A1 (en) | 2020-05-06 | 2021-11-11 | Molecular Partners Ag | Novel ankyrin repeat binding proteins and their uses |
| CA3178785A1 (en) | 2020-05-14 | 2021-11-18 | Nicolo RIGAMONTI | Multispecific proteins |
| EP4023218A1 (en) | 2020-12-02 | 2022-07-06 | S-Form Pharma | Combination therapy for patients having acute and/or persistent dyspnea |
| CA3202358A1 (en) | 2020-12-16 | 2022-06-23 | Andreas BOSSHART | Novel slow-release prodrugs |
| WO2022190016A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based multi-specific t-cell engagers |
| JP2024509890A (ja) | 2021-03-09 | 2024-03-05 | モレキュラー パートナーズ アクチェンゲゼルシャフト | プロテアーゼ切断可能なプロドラッグ |
| AU2022233791A1 (en) | 2021-03-09 | 2023-09-28 | Molecular Partners Ag | Novel darpin based cd123 engagers |
| WO2022190010A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based cd33 engagers |
| BR112023022439A2 (pt) | 2021-04-26 | 2023-12-26 | Celanese Eva Performance Polymers Llc | Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular |
| JP2024526081A (ja) | 2021-06-18 | 2024-07-17 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 敗血症及び敗血症性ショックを予測する方法 |
| KR20240041912A (ko) | 2021-06-29 | 2024-04-01 | 베리솔 게엠베하 | 체액내 셀레늄 결핍을 식별하기 위한 복합 바이오마커 |
| EP4145456A1 (en) | 2021-09-06 | 2023-03-08 | Bayer AG | Prediction of a change related to a macular fluid |
| KR20240122764A (ko) | 2021-12-14 | 2024-08-13 | 몰리큘라 파트너스 아게 | 이중 결합 특이성을 갖는 설계된 반복 도메인과 이의 용도 |
| CN119072492A (zh) | 2022-03-15 | 2024-12-03 | 艾德里诺医药公司 | 抗肾上腺髓质素（adm）抗体或抗adm抗体片段的稳定水性制剂 |
| WO2024023369A1 (en) | 2022-07-29 | 2024-02-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| AU2023315168A1 (en) | 2022-07-29 | 2025-02-13 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
| CN119731200A (zh) | 2022-08-01 | 2025-03-28 | 分子合作伙伴股份公司 | 经电荷修饰设计的重复结构域及其用途 |
| WO2024038307A1 (en) | 2022-08-19 | 2024-02-22 | Novartis Ag | Dosing regimens for sars-cov-2 binding molecules |
| WO2024059686A2 (en) * | 2022-09-15 | 2024-03-21 | The Regents Of The University Of California | Darpin backbones and rigidified electron microscopy imaging scaffolds |
| WO2024126793A1 (en) | 2022-12-15 | 2024-06-20 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 inhibitor for improvement of pulmonary function in critically ill patients |
| WO2024179981A1 (en) | 2023-02-27 | 2024-09-06 | Molecular Partners Ag | Darpins for use in reducing renal accumulation of drugs |
| CN120731367A (zh) | 2023-03-17 | 2025-09-30 | Pam治疗诊断有限公司 | 肽基甘氨酸α-酰胺化单加氧酶（PAM）的测定方法及其诊断用途 |
| WO2024200862A1 (en) | 2023-03-29 | 2024-10-03 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline |
| WO2025068313A1 (en) | 2023-09-25 | 2025-04-03 | Sphingotec Gmbh | A method for early diagnosis, early prediction, monitoring or prediction of severity of reduced graft function in a kidney transplantation patient |
| WO2025146491A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent |
| WO2025229075A1 (en) | 2024-05-03 | 2025-11-06 | Sphingotec Gmbh | A method for the specific determination of proenkephalin fragment 119-159 |
| WO2025248139A1 (en) | 2024-05-31 | 2025-12-04 | 4TEEN4 Pharmaceuticals GmbH | Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof |
| EP4675277A1 (en) | 2024-07-05 | 2026-01-07 | Predemtec AG | A method for diagnosing alzheimer´s disease or determining the risk of suffering from alzheimer´s disease |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5348867A (en) | 1991-11-15 | 1994-09-20 | George Georgiou | Expression of proteins on bacterial surface |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
| TR199902818T2 (xx) | 1997-04-07 | 2000-05-22 | Genentech, Inc. | Be�eri kullan�m i�in antikorlar ve be�eri kullan�m i�in antikorlar olu�turmak i�in y�ntemler. |
| DE69836729T2 (de) | 1997-04-07 | 2007-12-13 | Genentech, Inc., South San Francisco | Anti-vefg antibodies |
| CA2289691C (en) | 1997-04-23 | 2008-01-15 | Andreas Pluckthun | Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules |
| WO2000032823A1 (en) | 1998-12-02 | 2000-06-08 | Phylos, Inc. | Dna-protein fusions and uses thereof |
| ES2237429T3 (es) | 1999-06-08 | 2005-08-01 | Regeneron Pharmaceuticals, Inc. | Polipeptidos quimericos modificados con propiedades farmacocineticas mejoradas. |
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| DK1332209T3 (da) * | 2000-09-08 | 2010-03-29 | Univ Zuerich | Samlinger af repeatproteiner indeholdende repeatmoduler |
| RU2299208C2 (ru) * | 2001-05-08 | 2007-05-20 | Шеринг Акциенгезельшафт | Антраниламидпиридинамиды избирательного действия в качестве ингибиторов vegfr-2 и vegfr-3 |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| US7772188B2 (en) * | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| BRPI0417302A (pt) * | 2003-12-05 | 2007-03-06 | Compound Therapeutics Inc | inibidores de receptores de fator de crescimento endotelial vascular do tipo 2 |
| JP2008519590A (ja) * | 2004-11-12 | 2008-06-12 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 組換えニューカッスル病ウィルス |
| SI1861116T1 (sl) * | 2005-03-25 | 2015-12-31 | Regeneron Pharmaceuticals, Inc. | Formulacije antagonistov VEGF |
| RU2412249C2 (ru) | 2005-07-08 | 2011-02-20 | Юниверсити Оф Цюрих | Фаговый дисплей с применением котрансляционной транслокации слитых полипептидов |
| WO2008066752A2 (en) | 2006-11-22 | 2008-06-05 | Adnexus, A Bristol-Myers Squibb R & D Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir |
| EP2125016A2 (en) * | 2007-02-01 | 2009-12-02 | Genetech, Inc. | Combination therapy with angiogenesis inhibitors |
| ATE516814T1 (de) | 2007-02-02 | 2011-08-15 | Bristol Myers Squibb Co | 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese |
-
2009
- 2009-11-03 US US13/126,821 patent/US8901076B2/en active Active
- 2009-11-03 DK DK09756279.7T patent/DK2358746T3/da active
- 2009-11-03 BR BRPI0921469-0A patent/BRPI0921469B1/pt active IP Right Grant
- 2009-11-03 CN CN2009801536047A patent/CN102272148A/zh active Pending
- 2009-11-03 JP JP2011533752A patent/JP5954990B2/ja active Active
- 2009-11-03 MX MX2011004649A patent/MX2011004649A/es unknown
- 2009-11-03 EP EP09756279.7A patent/EP2358746B1/en active Active
- 2009-11-03 RU RU2015108838A patent/RU2650765C1/ru active
- 2009-11-03 WO PCT/EP2009/064483 patent/WO2010060748A1/en not_active Ceased
- 2009-11-03 ES ES09756279T patent/ES2836948T3/es active Active
- 2009-11-03 RU RU2011122201/10A patent/RU2550258C2/ru active
- 2009-11-03 MX MX2015010520A patent/MX359570B/es unknown
- 2009-11-03 CN CN201710092752.9A patent/CN107011425B/zh active Active
- 2009-11-03 KR KR1020117009012A patent/KR101698362B1/ko active Active
- 2009-11-03 NZ NZ592591A patent/NZ592591A/en unknown
- 2009-11-03 EP EP20196328.7A patent/EP3785735A1/en not_active Withdrawn
- 2009-11-03 AU AU2009319204A patent/AU2009319204B2/en active Active
- 2009-11-03 CA CA2742241A patent/CA2742241C/en active Active
-
2011
- 2011-04-28 IL IL212589A patent/IL212589A/en active IP Right Grant
-
2014
- 2014-10-28 US US14/525,553 patent/US20150344539A1/en not_active Abandoned
-
2015
- 2015-03-17 JP JP2015053249A patent/JP6329503B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110082528A (ko) | 2011-07-19 |
| EP2358746A1 (en) | 2011-08-24 |
| CN107011425B (zh) | 2021-01-01 |
| DK2358746T3 (da) | 2020-12-21 |
| BRPI0921469B1 (pt) | 2022-01-18 |
| IL212589A0 (en) | 2011-07-31 |
| US8901076B2 (en) | 2014-12-02 |
| CN102272148A (zh) | 2011-12-07 |
| BRPI0921469A2 (pt) | 2016-01-12 |
| ES2836948T3 (es) | 2021-06-28 |
| KR101698362B1 (ko) | 2017-01-20 |
| CA2742241C (en) | 2019-12-10 |
| CN107011425A (zh) | 2017-08-04 |
| RU2011122201A (ru) | 2012-12-10 |
| US20110207668A1 (en) | 2011-08-25 |
| EP3785735A1 (en) | 2021-03-03 |
| JP6329503B2 (ja) | 2018-05-23 |
| JP5954990B2 (ja) | 2016-07-20 |
| RU2650765C1 (ru) | 2018-04-17 |
| RU2550258C2 (ru) | 2015-05-10 |
| NZ592591A (en) | 2012-04-27 |
| MX359570B (es) | 2018-10-01 |
| JP2015133978A (ja) | 2015-07-27 |
| CA2742241A1 (en) | 2010-06-03 |
| JP2012507271A (ja) | 2012-03-29 |
| AU2009319204B2 (en) | 2014-11-13 |
| US20150344539A1 (en) | 2015-12-03 |
| AU2009319204A1 (en) | 2010-06-03 |
| EP2358746B1 (en) | 2020-09-16 |
| IL212589A (en) | 2017-01-31 |
| WO2010060748A1 (en) | 2010-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10646542B2 (en) | Modified binding proteins inhibiting the VEGF-A receptor interaction | |
| AU2009319204B2 (en) | Binding proteins inhibiting the VEGF-A receptor interaction | |
| HK1238258B (zh) | 抑制vegf-a受体相互作用的结合蛋白 | |
| HK1238258A1 (en) | Binding proteins inhibiting the vegf-a receptor interaction | |
| AU2014243418A1 (en) | Modified binding proteins inhibiting the VEGF-A receptor interaction | |
| HK1179876B (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
| HK1179876A (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
| HK1161726A (en) | Binding proteins inhibiting the vegf-a receptor interaction |